Gynecologic Cancers

Cancer, CV Risks Examined for Vaginal Estrogen Tx in Postmenopausal Women

By August 16, 2017

The data showed women with an intact uterus did not have a significantly different risk of stroke, invasive breast cancer, colorectal cancer, endometrial cancer, and pulmonary embolism/deep vein thrombosis (PE/DVT) between those who used vaginal estrogen and those who did not.

Cancer Rates Assessed Post-Endometrial Ablation

August 14, 2017

Leiomyomas, age younger than 35 years, at least 2 prior cesarean deliveries, and history of sterilization were factors that predisposed patients to post-ablation hysterectomy.

USPSTF Issues Draft Recommendation Statement on Ovarian Cancer Screening

July 21, 2017

Test isn't accurate enough to justify its use, U.S. Preventive Services Task Force says

Study Examines ACA Impact on Early Cancer Detection

May 19, 2017

For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.

Amneal Introduces New Strength of Thiotepa with Tepadina

By April 27, 2017

Tepadina, an alkylating agent, is indicated to reduce the risk of graft rejection when used with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.

Zejula Now Available for Recurrent Ovarian Cancer

By April 20, 2017

Zejula is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, in a randomized, prospectively designed Phase 3 clinical trial.

QoL Assessed After One Year of Ovarian CA Treatment

March 31, 2017

At one year, the mean global QOL score was lower for the standard chemotherapy group versus the concurrent-maintenance group.

Laparoscopic Hysterectomy Appropriate for Stage I Endometrial CA

March 29, 2017

The researchers found that disease-free survival was 81.3 and 81.6% in the TAH and TLH groups, respectively, at 4.5 years of follow-up.

Zejula Approved for Recurrent Ovarian Cancer, Primary Peritoneal Cancer

By March 28, 2017

The approval is supported by a randomized trial (n=533) of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received ≥2 prior treatments of platinum-based chemotherapy and were in a complete or partial response to the most recent treatment.

Are Antiemetic Prophylactics Being Overprescribed for Chemotherapy?

By March 24, 2017

Study authors identified a total of 8,545 patients undergoing 73,577 administrations of chemotherapy with minimal or low emetic risk.

Furosemide, Mannitol Assessed for Magnesium Wasting in Cervical CA Tx

March 21, 2017

After the second weekly cisplatin infusion, significant magnesium wasting was observed, regardless of whether furosemide or mannitol was used.

ASCO: HPV Vaccination Recommendations for Cervical Cancer Prevention

By March 20, 2017

The clinical practice guideline is the first for primary prevention of cervical cancer that is adapted to various areas in the world with different levels of socio-economic and structural resource settings.

Massage Improves Pain, Lymphedema in Female CA Patients

March 10, 2017

The researchers found that all participants reported a positive experience with aromatherapy massage.

CDC: Cancer Screening 'Considerably' Below Targets

March 07, 2017

The researchers found that screening test use remained considerably below HP2020 targets for selected cancer screening tests.

Coffee as Adjunct in Postoperative Gynecologic Surgery Care?

February 06, 2017

Coffee consumption speeds the time to bowel movement after complete staging surgery of gynecologic cancers, according to a study published in the February issue of the American Journal of Obstetrics & Gynecology.

FDA Approves Rubraca for Advanced Ovarian Cancer

By December 19, 2016

The Food and Drug Administration (FDA) has granted accelerated approval for Rubraca (rucaparib; Clovis Oncology) for the treatment of advanced ovarian cancer in women have been treated with two or more chemotherapies and whose tumors have deleterious BRCA mutation as identified by an FDA-approved companion diagnostic test.

Ten Year Outcomes of Uterine Artery Embolization vs. Hysterectomy

December 14, 2016

Hysterectomy can often be avoided in patients with uterine fibroids undergoing uterine artery embolization, according to a study published in the December issue of the American Journal of Obstetrics & Gynecology.

FDA Approves Avastin for Platinum-Sensitive Recurrent Ovarian Cancer

By December 07, 2016

Genentech announced that the Food and Drug Administration (FDA) has approved Avastin (bevacizumab) in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin alone, for the treatment of patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Accuracy of Genotyping for HPV Types 16/18 in Minor Abnormal Cytology

November 17, 2016

Testing for human papillomavirus (HPV) 16/18 has poor sensitivity for triaging women with minor abnormal cytology.

ANDA Accepted for Generic Doxil Injection

By October 31, 2016

Merrimack announced that the FDA has accepted for review the ANDA for generic Doxorubicin Hydrochloride (HCI) Liposome Injection.

Cancer Risks in Premenopausal Abnormal Uterine Bleeding Assessed

October 26, 2016

Premenopausal women with abnormal uterine bleeding have low risk of endometrial cancer and atypical hyperplasia, according to a review published online in BJOG: An International Journal of Obstetrics and Gynaecology.

Researchers ID Mutations in Uterine, Ovarian Carcinosarcomas

October 17, 2016

Carcinosarcomas (CSs) of the uterus and ovary have mutations in cancer genes previously identified in uterine and ovarian carcinomas and in genes encoding histones H2A and H2B, according to a study published online October 10 in the Proceedings of the National Academy of Sciences.

Does Ovarian Preservation Impact Cervical CA Prognosis?

October 13, 2016

For women with early-stage cervical adenocarcinoma, ovarian preservation does not impact survival, according to a study published in the October issue of the American Journal of Obstetrics & Gynecology.

HPV Vaccine Appears More Effective than Previously Believed

September 30, 2016

The vaccine against human papillomavirus (HPV) infection appears even more effective than previously believed, according to a report published online September 29 in JAMA Oncology.

Intensity-Modulated Radiation Therapy Tied to Reduced Toxicity in Certain Cancers

September 29, 2016

For women with cervical and endometrial cancer, treatment with intensity-modulated radiation therapy (IMRT) is associated with reduced toxicity.

Effectiveness of Neoadjuvant Chemo Examined in Ovarian CA Treatment

September 12, 2016

For patients with stage IIIC to IV ovarian cancer, neoadjuvant chemotherapy (NACT) use increased from 2003 to 2012, according to a study published online Sept. 6 in the Journal of Clinical Oncology.

Levonorgestrel IUD for Endometrical Cancer Prevention: Is It Cost-Effective?

September 12, 2016

Intrauterine device is potentially cost-effective for prevention of deaths from endometrial cancer

FDA: Clinicians May Be Misled by Ovarian Screening Test Claims

By September 09, 2016

The Food and Drug Administration (FDA) has issued a safety alert regarding the use of screening tests for ovarian cancer screening.

Oral Contraceptives May Be the Main Reason for Ovarian Cancer Drop

September 08, 2016

Ovarian cancer mortality is down dramatically in many parts of the world, and the use of oral contraceptives (OCs) may be a main reason why, according to a study published online in the Annals of Oncology.

Amneal Initiates Temporary Import of Cancer Drug Due to Shortage

By July 13, 2016

Amneal Biosciences announced that due to the current shortage of Bleomycin Sulfate for Injection, USP, 15 Units and 30 Units per vial, they have initiated a temporary importation of Bleomycin Sulfate Powder for Injection 15,000 IU per vial to the market.